Alumis Reports Positive Phase 3 Results for Envudeucitinib in Psoriasis, Plans NDA, and Extends Cash Runway

summarizeSummary

Alumis Inc. announced highly positive Phase 3 results for its lead candidate, envudeucitinib, in moderate-to-severe plaque psoriasis, alongside year-end financial results and an extended cash runway into Q4 2027.

check_boxKey Events

• Positive Phase 3 Results

  Envudeucitinib achieved highly significant primary and secondary endpoints in moderate-to-severe plaque psoriasis, showing leading skin clearance (approximately 65% PASI 90, and over 40% PASI 100 at Week 24) and a favorable safety profile.

• NDA Submission Planned

  The company plans to submit a New Drug Application (NDA) for envudeucitinib in plaque psoriasis in the second half of 2026.

• Extended Cash Runway

  Alumis expects its existing cash, cash equivalents, and marketable securities as of December 31, 2025, combined with $324.4 million net proceeds from its January 2026 public offering, to fund operating expenses and capital expenditure requirements into the fourth quarter of 2027.

• Upcoming Clinical Milestones

  Potentially pivotal Phase 2b SLE topline data for envudeucitinib is anticipated in Q3 2026, and an update on the unified TYK2 franchise development strategy is expected in Q2 2026.

auto_awesomeAnalysis

This 8-K filing is highly significant for Alumis, primarily driven by the positive Phase 3 topline results for envudeucitinib in moderate-to-severe plaque psoriasis. The drug demonstrated leading skin clearance and a favorable safety profile, significantly de-risking the lead asset and paving the way for an NDA submission in the second half of 2026. Additionally, the company reported year-end 2025 financial results and confirmed an extended cash runway into the fourth quarter of 2027, bolstered by a recent $345.1 million public offering. This combination of strong clinical data and financial stability provides a clear path forward for the company's lead program and pipeline. Investors should monitor the upcoming NDA submission and Phase 2b SLE data.